Barclays
FRTX

Barclays’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Barclays’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-19
Closed -$60K – 7728
2013
Q3 		$60K Buy
+19
New +$143K ﹤0.01% 5963

Other funds holding FRTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barclays's FRTX Position: Q2 2018 in Review

Barclays sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q2 2018, closing a stake of 1 share.

Barclays first reported a position in FRTX in Q2 2013 and held it in 6 quarters. The position peaked at $184K in Q2 2013. 28 funds tracked by Wall St. Rank hold FRTX as of Q2 2018.

  • Barclays reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • Barclays sold 1 Fresh Tracks Therapeutics, Inc. Common Stock share in Q2 2018.
  • Barclays first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q2 2013 and held it in 6 quarters.
  • Barclays's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $184K in Q2 2013.
  • 28 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q2 2018.

Based on Barclays's 13F filing for Q2 2018, filed 14 Aug 2018.